Burosumab-twza (Crysvita) for a rare inherited form of rickets; ibalizumab-uiyk 
(Trogarzo) for human immunodeficiency virus type 1 infection; and 
tildrakizumab-asmn (Ilumya) for adults with moderate-to-severe plaque psoriasis.